A Handheld Microchip for GC analysis of breath to screen for COVID-19

  • Funded by National Institutes of Health (NIH)
  • Total publications:4 publications

Grant number: 1U18TR003787-01

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $1,026,672
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Xiao-An Fu
  • Research Location

    United States of America
  • Lead Research Institution

    University Of Louisville
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Project Summary The COVID-19 pandemic has caused unprecedented societal suffering and economic disruption. In theUnited States, more than six million people have contracted COVID-19 and more than one hundred ninetythousand patients have died of this disease to date. Although current COVID-19 diagnostic testing technologiesare critical for slowing the spread of the virus and preventing future outbreaks, they are not practical for field use.Current diagnostic tests are cumbersome to perform because they use aqueous solutions, require multiple steps,and hours-to-days to obtain results. Since the US began to reopen the economy in May, there has been asignificant increase in the number of COVID-19 cases. Therefore, there is an urgent need to develop a diagnosticapproach that is non-invasive, portable, and can rapidly provide test results. The overall goal of the project is to develop a mobile breath analysis technology for rapid screening forCOVID-19 using a handheld breath collection tool and a portable GC with a photoionization detector (PID). Thehandheld tool will be a closed system for trapping select volatile organic compounds (VOCs) on a microfabricatedchip. The captured VOCs will be eluted with ethanol and then analyzed using a commercially available, portableGC-PID instrument. Artificial intelligence (AI) and machine learning algorithms will be applied to recognize theVOC pattern that correlates with COVID-19 infection. The central innovation is the microfabricated chip thatcaptures carbonyl compounds in exhaled breath and thus serves as a preconcentrator, which enables analysisof carbonyl VOCs by the portable GC-PID. The hypothesis is that the carbonyl metabolome in exhaled breath isdirectly related to the body's reaction to the novel coronavirus infection, and changes in the carbonyl VOCcomposition in exhaled breath relative to healthy controls can be used to detect both symptomatic andasymptomatic COVID-19 patients. Three specific aims are proposed to fulfill the overall goal. Aim 1 is to build a disposable handheld breathanalyzer tool for concentrating carbonyl VOCs. Aim 2 is to identify VOC patterns in the breath of COVID-19patients by machine learning algorithms. Aim 3 is to integrate portable GC technology with the breath samplingtool for COVID-19 screening guided by an AI system. The University of Louisville is uniquely suited to rapidlytransition the microchip technology to field use because of the PI and Co-PI's experience in breath analysis andtranslational research, and the project team's experience in virology, infectious diseases, biostatistics, andartificial intelligence as well as the state-of-the-art facilities that include a MicroNano Technology Center,Biosafety Level 3 Regional Biocontainment Lab, and an NIH-funded REACH program.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Withaferin A as a Potential Therapeutic Target for the Treatment of Angiotensin II-Induced Cardiac Cachexia.

Ketamine for Monitored Anesthesia Care During Transcatheter Aortic Valve Replacement.

Implementing an electronic hand hygiene system improved compliance in the intensive care unit.

Outcomes and Risk Factors for Cardiovascular Events in Hospitalized COVID-19 Patients.